Drug Trial Radar · NCT04314986
Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers
Last checked: Nov 19, 2026Latest source record: Nov 16, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jun 28, 2019
Primary completion
Sep 18, 2019
Study completion Sep 18, 2019
Sponsor
- Lead sponsor
- Arthrosi TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Mar 19, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to assess multiple ascending doses of AR882 in healthy adult males.
Conditions
- Healthy Volunteers
Interventions
Cohort 1: AR882 or placeboDrug
AR882 or matching placebo administered once daily for 10 days
Cohort 2: AR882 or placeboDrug
AR882 or matching placebo administered once daily for 10 days.
Cohort 3: AR882 or placeboDrug
AR882 or matching placebo administered once daily for 10 days
Cohort 4: AR882 or placeboDrug
AR882 or matching placebo administered once daily for 10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety profile of AR882 based on incidence of adverse eventsTime frame: 22 Days
- To evaluate the safety profile of AR882 based on incidence of abnormal laboratory findingsTime frame: 22 Days
- To evaluate the safety profile of AR882 based on incidence of abnormal electrocardiogram findingsTime frame: 22 Days
- To evaluate the safety profile of AR882 based on incidence of abnormal vital signs findingsTime frame: 22 Days
- Area under the curve (AUC) for plasma AR882Time frame: 15 Days
- Time to maximum plasma concentration (Tmax) for AR882Time frame: 15 Days
- Maximum plasma concentration (Cmax) for AR882Time frame: 15 Days
- Apparent terminal half-life (t1/2) for AR882Time frame: 15 Days
- Amount excreted (Ae) into urine for AR882Time frame: 15 Days
- Fractional Excretion (FEUA) for AR882Time frame: 15 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network Pty, Ltd.
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.